化学
追踪
铅化合物
计算生物学
组合化学
蛋白酶
铅(地质)
口译(哲学)
立体化学
计算机科学
酶
生物化学
生物
程序设计语言
体外
古生物学
操作系统
作者
Maren Kuhnert,Helene Köster,Ruben Bartholomäus,Ah Young Park,Amir Shahim,A. Heine,H. Steuber,Gerhard Klebe,Wibke E. Diederich
标识
DOI:10.1002/anie.201411206
摘要
Successful lead optimization in structure-based drug discovery depends on the correct deduction and interpretation of the underlying structure-activity relationships (SAR) to facilitate efficient decision-making on the next candidates to be synthesized. Consequently, the question arises, how frequently a binding mode (re)-validation is required, to ensure not to be misled by invalid assumptions on the binding geometry. We present an example in which minor chemical modifications within one inhibitor series lead to surprisingly different binding modes. X-ray structure determination of eight inhibitors derived from one core scaffold resulted in four different binding modes in the aspartic protease endothiapepsin, a well-established surrogate for e.g. renin and β-secretase. In addition, we suggest an empirical metrics that might serve as an indicator during lead optimization to qualify compounds as candidates for structural revalidation.
科研通智能强力驱动
Strongly Powered by AbleSci AI